Changes in circulating filarial antigen status in previously positive individuals: Lessons for treatment monitoring and pre-transmission assessment surveys
PLOS Neglected Tropical Diseases · 04.02.2025 · 19 (2) · e0012802
DOI: 10.1371/journal.pntd.0012802 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 04.02.2025. Verfasst von Derrick Adu Mensah und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. Hauptthemen laut MEDLINE: Antigens, Helminth, Elephantiasis, Filarial, Wuchereria bancrofti. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung‑BMBF), German Research Foundation – DFG, European and Developing Countries Clinical Trial Partnership (EDCTP2) programme and supported by the European Union.
Abstract (Originalsprache)
Background The Global Programme to Eliminate Lymphatic Filariasis has made significant gains through mass drug administration (MDA) of Ivermectin/Albendazole. Periodic evaluation of the MDA programme in lymphatic filariasis elimination is particularly useful in determining end points for stopping the programme. This is a follow-up study that sought to examine the effects of additional time and MDA intake on antigenemia seroreversion in persons who had previously tested positive for LF using the Filarial Test Strip (FTS) and the TropBio ELISA over a period of 1–5 years. Methodology/principal findings A total of 542 individuals, from the Kassena Nankana East Municipal (N = 340) and Nabdam districts (N = 202) in the Upper East Region of Ghana, who had previously tested either positive (N = 446) or negative (N = 96) for FTS-CFA, participated in the study. Two follow-up visits were conducted; 1–4 years (follow-up-1) and 2–5 years (follow-up-2) after the baseline visit. Of the 446 FTS-CFA positives, 175 (39.2%) did not receive additional MDA (ivermectin/Albendazole) after the baseline visit. Overall, from the two follow-up visits, 159/175 (90.9%) FTS-CFA+ participants who did not receive any additional Ivermectin/Albendazole and 226 out of the 271 (83.4%) with additional MDA treatment became CFA negative. A total of 120 randomly selected baseline FTS-CFA+ samples were tested with Og4C3 TropBio ELISA and only 44/120 (36.7%) were found positive. Of these 44 participants, 12 (27.3%) completely became CFA negative and an additional 18 (40.9%) had reduced antigen levels during the follow-up. Likewise, all three previously/baseline microfilariae positive persons had become amicrofilaremic. Conclusions/significance In the present work, it has been shown that >90% of the previous CFA positive individuals seroreverted in 1 to 5 years post-baseline without additional MDA. The FTS is a more sensitive diagnostic tool that plausibly detects residual CFA in blood. The impact and influence of time as compared to additional ivermectin/Albendazole intake, on CFA seroreversion in this study was significant (p < 0.001).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Microbiology, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
- Kumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
- Department of Pathobiology, School of Veterinary Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
- German Center for Infection Research (DZIF), partner site Munich, Munich, Germany.
- Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany.
ORCID-Profile: Alexander Yaw Debrah
Förderung
- German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung‑BMBF)
- German Research Foundation – DFG
- European and Developing Countries Clinical Trial Partnership (EDCTP2) programme and supported by the European Union
- the German Federal Ministry of Education and Research
- Deutsches Zentrum für integrative Biodiversitätsforschung Halle-Jena-Leipzig
Zitieren
APA
Mensah, D. A., Opoku, V. S., Boateng, J., Opoku, J., Osei-Mensah, J., Gyasi, C., Obeng, P., Ahiadorme, M., Atisu, P. D., Kutu, E. D., Kroidl, I., Klarmann-Schulz, U., Hoerauf, A., Debrah, L. B., & Debrah, A. Y. (2025). Changes in circulating filarial antigen status in previously positive individuals: Lessons for treatment monitoring and pre-transmission assessment surveys. PLOS Neglected Tropical Diseases, 19(2), e0012802. https://doi.org/10.1371/journal.pntd.0012802
Vancouver
Mensah DA, Opoku VS, Boateng J, Opoku J, Osei-Mensah J, Gyasi C, et al. Changes in circulating filarial antigen status in previously positive individuals: Lessons for treatment monitoring and pre-transmission assessment surveys. PLOS Neglected Tropical Diseases. 2025;19(2):e0012802. doi:10.1371/journal.pntd.0012802
BibTeX
@article{Mensah2025,
author = {Mensah, Derrick Adu and Opoku, Vera Serwaa and Boateng, John and Opoku, John and Osei-Mensah, Jubin and Gyasi, Charles and Obeng, Prince and Ahiadorme, Monica and Atisu, Prince Dennis and Kutu, Emmanuel Donawobuge and Kroidl, Inge and Klarmann-Schulz, Ute and Hoerauf, Achim and Debrah, Linda Batsa and Debrah, Alexander Yaw},
title = {Changes in circulating filarial antigen status in previously positive individuals: Lessons for treatment monitoring and pre-transmission assessment surveys},
journal = {PLOS Neglected Tropical Diseases},
year = {2025},
volume = {19},
number = {2},
pages = {e0012802},
doi = {10.1371/journal.pntd.0012802}
}
EUVIMED